Kamfomen®

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT KAMFOMEN®

Composition:

Active substances: 1 can contains levomenthol 0.06 g; refined castor oil 0.61 g; camphor oil 10 % for external use 0.61 g; eucalyptus oil 0.61 g; nitrofural 0.002 g (2 mg);

Excipients: ethanol 96 %, isopropyl myristate, propellant 134a.

Pharmaceutical form. Aerosol.

Main physicochemical properties: greenish-yellow or yellow liquid with a characteristic odor.

Pharmacotherapeutic group.

Preparations used in throat diseases. Antiseptics. ATC code R02A A20.

Pharmacological Properties.

Pharmacodynamics.

Has anti-inflammatory and antimicrobial effects provided by eucalyptus oil and nitrofurazone, as well as anti-edematous effect due to the action of camphor oil and other components of the drug. Reflex reactions associated with irritation of sensory nerve endings play a significant role in the mechanism of action. Stimulation of mucosal receptors is accompanied by enhanced production and release of enkephalins, endorphins, and peptides, which play an important role in regulating pain sensations, vascular permeability in the nasal cavity, oral cavity, pharynx, and other processes.

Pharmacokinetics.

The drug is intended for local application; therefore, its activity does not correlate with the concentration of active substances in blood plasma.

Clinical characteristics.

Indications.

As part of complex treatment of acute inflammatory conditions of the upper respiratory tract: pharyngitis and pharyngolaryngitis, rhinitis, as well as in the postoperative period after tonsillectomy and polyp removal.

Contraindications.

Hypersensitivity to any component of the drug, nitrofurale derivatives; eczema; whooping cough; predisposition to bronchospasm, seizures.

It is not recommended to prescribe to patients working in environments with high levels of dust exposure (flour, tobacco, asbestos, and cement industries).

Interaction with other medicinal products and other types of interactions.

Not established.

Special precautions for use.

Do not spray near fire.

Avoid contact of the product with eyes. Individuals prone to allergies should consult a doctor before use.

Treatment of children should be carried out under medical supervision.

Use during pregnancy or breastfeeding.

No contraindications for the use of the product during pregnancy or breastfeeding have been identified.

Ability to affect reaction rate when driving or operating machinery.

Not established.

Administration and Dosage

Before inhalation from the spray, remove the protective cap. Insert the spray into the nasal or oral cavity to a depth of 0.5 cm and press the base. This releases the contents of the bottle in a finely dispersed form. Each spray delivers 0.1 g of the drug.

Camphomen should be sprayed into the nasal or oral cavity during inhalation, 2–3 sprays, 3–4 times daily after meals. The duration of treatment is 5–7 days.

Symptoms of the illness usually resolve within 3–5 days.

Children

Not recommended for children under 5 years of age.

Overdose

May result in an intensification of adverse reactions. Symptomatic treatment is recommended.

Side effects.

Immune system side effects: allergic reactions, including itching, rash, mucosal swelling of the nose and throat.

Respiratory system side effects: laryngospasm, hoarseness, shortness of breath.

Nervous system side effects: headache, dizziness; seizures caused by camphor are possible.

Local effects: burning sensation due to increased individual sensitivity to the components of the drug.

Shelf life. 2 years.

Do not use the drug after the expiry date stated on the packaging.

Storage conditions.

Keep out of reach of children.

Store in the original packaging at a temperature not exceeding 25 °C.

Protect from falls, impacts, and exposure to direct sunlight.

Packaging.

30 g in an aluminum aerosol can; 1 can with a spray applicator in a carton.

Supply category. Over-the-counter.

Manufacturer. JSC "Stoma", Ukraine.

Manufacturer's address.

3 Newton Street, Kharkiv, 61105, Ukraine.